Esophagus Cancer: Clinical Trials

115 trials for Esophagus Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 31 unknown, 25 recruiting, 7 terminated. 33 Phase 2, 30 Not applicable, 25 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 233Completed 14, Unknown 7, Recruiting 4, Not yet recruiting 3, Active not recruiting 2, Terminated 2, Withdrawn 1
Not applicable30Unknown 12, Recruiting 9, Completed 4, Terminated 3, Not yet recruiting 1, Withdrawn 1
Phase 125Completed 9, Unknown 6, Recruiting 5, Active not recruiting 1, Not yet recruiting 1, Suspended 1, Terminated 1, Withdrawn 1
Phase 36Completed 3, Unknown 2, Recruiting 1

Follow Esophagus Cancer: new trials by email Literature Review of Esophagus Cancer trials Research Report on Esophagus Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
18F-G1 - Solid Tumor Malignancies, Hematologic Cancer
RecruitingPeking University First Hospital1202026-09-082026-09-28
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D) - Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Phase 1RecruitingUniversity of Texas Southwestern Medical Center152026-08-282026-09-02
Statewide Unified Network for Remote Intervention of Strength and Exercise
Exercise, Stretching - Gastric Cancer (Diagnosis), Esophagus Cancer
Not applicableNot yet recruitingAdventHealth Translational Research Institute1202026-07-012026-05-19
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
CRPA1A2 - Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
Phase 1Not yet recruitingCorregene Biotechnology Co., Ltd1922026-05-292026-05-13
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
Esophagus Cancer
Not yet recruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical University502026-02-012026-02-27
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
Fosrolapitant and Palonosetron Hydrochloride for Injection combined with dexamethasone acetate, For injection, fosapirtan dimeglumine combined with palonosetron hydrochloride and dexamethasone acetate - Esophagus Cancer, Lung Cancer
Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1202025-11-012026-06-01
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Ivonescimab, 5-Fluorouracil, Oxaliplatin - Stomach Cancer Stage IV, Esophagus Cancer
Phase 2RecruitingMassachusetts General Hospital402025-10-102026-08-28
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Palbociclib, Afatinib(30mg), Afatinib(40mg) - Esophagus Cancer
Phase 1 / Phase 2RecruitingWest China Hospital452025-09-102025-12-03
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum - Esophagus Cancer
Phase 2Not yet recruitingFujian Cancer Hospital602025-08-012025-07-20
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Tislelizumab, albumin-bound paclitaxel, Nedaplatin - Esophagus Cancer
Phase 2Not yet recruitingThe First Affiliated Hospital of Xiamen University262025-07-302025-06-13
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Esophagus Cancer
RecruitingCentral South University2002025-06-012026-07-07
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Tislelizumab - Esophagus Cancer
Phase 2Not yet recruitingFujian Cancer Hospital202025-05-152025-02-28
Target-specific immunoPET Imaging of Digestive System Carcinoma
[68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4 - Malignancy, Digestive Cancer
Not applicableRecruitingRenJi Hospital4002024-12-042025-12-31
Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer
Eso-SPONGEĀ® - Esophageal Cancer, Esophagus Cancer
Active not recruitingAesculap AG442024-10-072026-11-09
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
Esophagus Adenocarcinoma, Esophagus Cancer
Active not recruitingLudwig-Maximilians - University of Munich202024-10-062024-11-12
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
Standard assistance, Enhanced assistance - Bone Cancer, Brain Cancer
Not applicableCompletedWashington University School of Medicine332024-10-042025-08-26
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
Esophagus Cancer, Gastric Cancer
UnknownSt. James's Hospital, Ireland21882024-08-202024-08-13
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms
Phase 1 / Phase 2WithdrawnNational Cancer Institute (NCI)2024-08-022024-08-05
Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer
chemo-radiation - Esophagus Cancer
RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1202024-05-012024-04-26
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Tislelizumab (BGB-A317) with chemoradiotherapy - Esophagus Cancer
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences902024-04-012024-12-27

Showing 20 of 115. Sign in to see all of them.

Narrower conditions

Esophageal Neoplasms (115)  ·  Stomach Neoplasms (35)  ·  Pancreatic Neoplasms (18)  ·  Lung Neoplasms (15)  ·  Breast Neoplasms (13)  ·  Colorectal Neoplasms (13)  ·  Neoplasms (11)  ·  Colonic Neoplasms (10)  ·  Liver Neoplasms (10)  ·  Ovarian Neoplasms (10)  ·  Prostatic Neoplasms (9)  ·  Rectal Neoplasms (9)  ·  Urinary Bladder Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Uterine Cervical Neoplasms (6)

Broader conditions

Digestive System Diseases (115)  ·  Gastrointestinal Diseases (115)  ·  Neoplasms by Site (115)  ·  Digestive System Neoplasms (114)  ·  Esophageal Diseases (114)  ·  Gastrointestinal Neoplasms (112)  ·  Head and Neck Neoplasms (110)  ·  Neoplasms (104)  ·  Stomach Diseases (35)  ·  Intestinal Diseases (26)  ·  Neoplasms by Histologic Type (25)  ·  Intestinal Neoplasms (24)  ·  Endocrine Gland Neoplasms (23)  ·  Endocrine System Diseases (23)  ·  Lung Diseases (23)

Interventions

Paclitaxel (8)  ·  Cisplatin (7)  ·  Radiotherapy (6)  ·  tislelizumab (6)  ·  Carboplatin (5)  ·  Fluorouracil (5)  ·  Oxaliplatin (5)  ·  Albumin-Bound Paclitaxel (4)  ·  Docetaxel (4)  ·  Esophagectomy (3)  ·  Radiation (3)  ·  tisotumab vedotin (3)  ·  Blood Specimen Collection (2)  ·  Capecitabine (2)  ·  Chemoradiotherapy (2)

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5)  ·  RenJi Hospital (5)  ·  Washington University School of Medicine (5)  ·  Chongqing Precision Biotech Co., Ltd (3)  ·  Mayo Clinic (3)  ·  Seagen Inc. (3)  ·  Sun Yat-sen University (3)  ·  The First Affiliated Hospital of Henan University of Science and Technology (3)  ·  Chinese Academy of Medical Sciences (2)  ·  Fujian Cancer Hospital (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Ohio State University Comprehensive Cancer Center (2)  ·  SCRI Development Innovations, LLC (2)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (2)  ·  Shanghai Zhongshan Hospital (2)

Countries

China (50)  ·  United States (33)  ·  France (5)  ·  United Kingdom (5)  ·  Denmark (4)  ·  Australia (3)  ·  Belgium (3)  ·  Canada (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Italy (2)  ·  Brazil (1)  ·  Finland (1)  ·  Hungary (1)

Top investigators

Diansan Su, Dr. (2)  ·  Gregory Vlacich, M.D., Ph.D. (2)  ·  Johann de Bono, Professor (2)  ·  Shegan Gao, MD, PhD (2)  ·  Ajay Goel, PhD (1)  ·  Akhil Kumar, MD (1)  ·  Akos Czibere, MD, PhD (1)  ·  Alfredo Yoldi, MD (1)  ·  Anouchka Modesto, Doctor (1)  ·  Benjamin Tomlinson, MD (1)  ·  Brennan Spiegel, MD, MSHS (1)  ·  Caihong Dong, MD, PhD (1)  ·  Clarisse Dromain, MD, phD (1)  ·  Daniela Molena, MD (1)  ·  David R. Spigel, MD (1)

Results publications

PMID 37496366, PMID 41044356, PMID 19784073, PMID 20351330, PMID 20354452, PMID 23148692, PMID 24224128, PMID 24371038, PMID 25220908, PMID 26038198, PMID 26101715, PMID 26248577, PMID 26805559, PMID 27208039, PMID 27223606, PMID 27266524, PMID 27742014, PMID 27951496, PMID 28167973, PMID 28181403, PMID 28223550, PMID 28230778, PMID 28974061, PMID 29149611, PMID 29248399, PMID 30745090, PMID 30971301, PMID 31036088, PMID 31156297, PMID 31265819, PMID 31278907, PMID 31796521, PMID 32983991, PMID 33014774, PMID 33188449, PMID 34202917, PMID 34981300, PMID 35108470, PMID 36922805, PMID 36990609, PMID 37130329, PMID 37195667, PMID 37335662, PMID 37797632, PMID 37852261, PMID 38514081, PMID 39562048, PMID 39933757, PMID 39978682, PMID 40206581

NIH funding

2018 (1), R01CA252211 (1)